top of page

iCAN Synergizes with Synteract

Research Triangle Park, NC - Dec. 13th, 2018 - Recently, iCAN Research President, Leanne West, and iCAN Director, Amy Ohmer paid a visit to the Synteract offices located in Raleigh, North Carolina. Joining the meeting were colleagues, Dr. Martine Dehlinger-Kremer, VP, Pediatric Development Europe, Lynne Georgopoulos, Vice President, Pediatric Development Americas, Elisabeth Schrader, Executive Director, Program Strategy, Pediatrics and Rare Diseases and Laura Deason, Manager, Patient and Site Advocacy.

Synteract, an innovative contract research organization (CRO) providing full, phase I-IV services enabling drug development companies to bring new medicines to market, signed a memo of understanding in June, 2018 to partner with the International Children’s Advisory Network (iCAN Research). In November, 2018, Synteract acquired KinderPharm, a specialty pediatric CRO, focused on advancing pediatric drug development across all phases of clinical research. Like Synteract,

Empowering Pediatric Patients (L-R) A.Ohmer, E. Schrader, L. West, M. Dehlinger-Kremer, L.Deason

has extensive experience in helping clients efficiently navigate the complex pediatric regulatory environments in the U.S. and Europe and provides advanced pharmacometric modeling and clinical trial simulation technologies coupled with juvenile formulation and toxicology services. Through their existing collaboration, both iCAN Research and Synteract understand the need to include the pediatric patient voice at all stages of clinical research trials.

"By providing children with the opportunity to share their expertise in living with acute, chronic, multiple and rare disease, we are providing a chance to improve the outcomes, even beyond medical science as there is no better testimony that hearing from the young person living with the many challenges that a diagnosis brings", shared iCAN Director, Amy Ohmer.

bottom of page